We are currently in discussions with the company Ingedata to segment lesions in imaging data from patients in the Immunosarbor trial. This will give us information on how drug ImmunoSABR affects lesions in time. In this project, we are collaborating with “Data Hub” and MEMIC, who will manage the secure transfer of data. In this project AI Redbrick annotation platform will be used. https://redbrickai.com/ The platform’s AI capabilities will support the project in identifying key patterns and insights from the data.
